Two cases of delayed onset of immune‐related adverse events after discontinuation of nivolumab in patients with metastatic renal cell cancer

Delayed onset of immune‐related adverse events following immune‐checkpoint inhibitor discontinuation is underrecognized because of little available evidence.

[1]  L. Lipton,et al.  Very Delayed Acute Hepatitis after Pembrolizumab Therapy for Advanced Malignancy: How Long Should We Watch? , 2021, Current oncology.

[2]  G. Pond,et al.  Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors , 2020, Journal for ImmunoTherapy of Cancer.

[3]  R. Bell,et al.  Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance , 2019, Journal of Immunotherapy for Cancer.

[4]  I. Trocóniz,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors , 2019, Clinical Pharmacokinetics.

[5]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[6]  R. Motzer,et al.  Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[7]  J. Cebon,et al.  Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti-PD-1 Therapy. , 2018, The oncologist.

[8]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[9]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[10]  A. Razak,et al.  A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  J. Taube,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  K. Kerr,et al.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.